Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD74 | P04233 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23723295 | 1.00 | CD74 (0.44) | CD74MIFHDAC3HDAC1HDAC2 | |
| SCHEMBL30633643 | 0.88 | CD74 (0.43) | CD74MIFHDAC3HDAC1HDAC2 | |
| SCHEMBL23745973 | 0.88 | CD74 (0.43) | CD74MIFHDAC3HDAC1HDAC2 | |
| SCHEMBL23723370 | 0.83 | CD74 (0.36) | CD74MIFHDAC3HDAC1HDAC2 | |
| SCHEMBL23723367 | 0.83 | CD74 (0.36) | CD74MIFHDAC3HDAC1HDAC2 | |
| SCHEMBL23723347 | 0.75 | ALDH1A1 (0.41) | — | |
| SCHEMBL23723345 | 0.75 | ALDH1A1 (0.41) | — | |
| SCHEMBL23723267 | 0.75 | KMT2A (0.41) | — | |
| SCHEMBL23723269 | 0.75 | KMT2A (0.41) | — | |
| SCHEMBL30633627 | 0.74 | CD74 (0.35) | CD74MIFHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2021155439-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | MAOB, LOX, LPO | CD74 2182/4885MIF 3666/4885HDAC3 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.